Stratos Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Stratos Wealth Advisors's REGN Position: Q2 2026 in Review
Stratos Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.75% in Q2 2026, selling an estimated $44.2K and leaving 8,630 shares worth $5.38M. The position accounts for 0.3% of the portfolio, ranked #79.
Stratos Wealth Advisors first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $9.12M in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Stratos Wealth Advisors held 8,630 shares of Regeneron Pharmaceuticals worth $5.38M as of Q2 2026.
- Stratos Wealth Advisors sold 65 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $44.2K.
- Regeneron Pharmaceuticals made up 0.3% of Stratos Wealth Advisors's portfolio in Q2 2026, its #79 holding.
- Stratos Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
- Stratos Wealth Advisors's Regeneron Pharmaceuticals position peaked at $9.12M in Q2 2024.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Stratos Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.